Fig. 6: Recovered MolT-II T cells can control tumor growth in vivo.
From: Dysfunctional CD4 T cells in an oncovirus-specific TCR-transgenic in vivo model
A Depending on the experimental group, C57BL/6 mice received a transfer of 1x107 MolT-II cells on day -15, followed by vaccination with the helper epitope envH, combined with the dominant CTL epitope gagL emulsified in IFA (or only IFA) on day -14, and then subcutaneous injection with 2×103 RMA tumor cells. B Graph shows the survival of RMA tumor-bearing mice that received control treatment (IFA only, n = 16), a transfer of MolT-II cells (n = 8), vaccination with envH + gagL (n = 16), or vaccination with envH + gagL and transfer of MolT-II cells (n = 15), (data pooled from two independent experiments, statistical significance was determined by Log-rank test; p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; MolT-II vs. envH + gagL p < 0.0001, MolT-II vs. MolT-II + envH + gagL p < 0.0001, envH + gagL vs. MolT-II + envH + gagL p = 0.0209). C Graphs showing the outgrowth of RMA tumors among the different groups over time.
